

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|--------------------------|
| Application Number | 10/609,298 |
| Filing Date | June 27, 2003 |
| First Named Inventor | Sommadossi <i>et al.</i> |
| Group Art Unit | 1623 |
| Examiner Name | Unassigned |
| Attorney Docket Number | 06171.105059 IDX 1017 |

Sheet 1 of 7

3405771 1

U.S. PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages/ Relevant Figures Appear | T ⁶ |
|------------------------|--------------------------|----------------------|-------------------------|--|--|--|----------------|
| | | Number | Kind Code (if known) | | | | |
| TM | AA | 3,798,209 | | Wilkowski, <i>et al.</i> | 03-19-1974 | | |
| | AB | RE29,835 | | Witkowski <i>et al.</i> | 11-14-1978 | | |
| | AC | 4,522,811 | | Eppstein <i>et al.</i> | 06-11-1985 | | |
| | AD | 4,957,924 | | Beauchamp | 09-18-1990 | | |
| | AE | 5,149,794 | | Yatvin <i>et al.</i> | 09-22-1992 | | |
| | AF | 5,157,027 | | Biller <i>et al.</i> | 10-20-1992 | | |
| | AG | 5,194,654 | | Hostetler <i>et al.</i> | 03-16-1993 | | |
| | AH | 5,223,263 | | Hostetler <i>et al.</i> | 06-29-1993 | | |
| | AI | 5,256,641 | | Yatvin <i>et al.</i> | 10-26-1993 | | |
| | AJ | 5,411,947 | | Hostetler <i>et al.</i> | 05-02-1995 | | |
| | AK | 5,463,092 | | Hostetler <i>et al.</i> | 10-31-1995 | | |
| | AL | 5,543,389 | | Yatvin <i>et al.</i> | 08-06-1996 | | |
| | AM | 5,543,390 | | Yatvin <i>et al.</i> | 08-06-1996 | | |
| | AN | 5,543,391 | | Yatvin <i>et al.</i> | 08-06-1996 | | |
| | AO | 5,554,728 | | Basava <i>et al.</i> | 09-10-1996 | | |
| TM | AP | 6,312,662 | B1 | Erion <i>et al.</i> | 11-06-2001 | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages/ Relevant Figures Appear | T ⁶ |
|------------------------|--------------------------|-------------------------|-----------|--------------------------------------|--|---|--|----------------|
| | | Office ³ | Number | Kind Code ² (if known) | | | | |
| TM | AQ | DE | 3,512,781 | A1 | Soc. Nat. Elf Aquitaine | 10-17-1985 | | |
| | AR | EP | 0,180,276 | B1 | Stamicarbon B.V. | 12-19-1988 | | |
| | AS | EP | 0,350,287 | B1 | Chimerix | 09-27-2000 | | |
| | AT | EP | 0,650,371 | B1 | State of Oregon | 11-15-2000 | | |
| | AU | WO | 89/02733 | A1 | Regents of the Univ. of California | 04-06-1989 | | |
| | AV | WO | 90/00555 | A1 | Vical Inc. | 01-25-1990 | | |
| TM | AW | WO | 91/16920 | A1 | Vical Inc. | 11-14-1991 | | |

Examiner Signature /Traviss McIntosh III/ (07/24/2006)


Date
Considered

07/24/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

2 of 7

Complete if Known

| | |
|------------------------|--------------------------|
| Application Number | 10/609,298 |
| Filing Date | June 27, 2003 |
| First Named Inventor | Sommadossi <i>et al.</i> |
| Group Art Unit | 1623 |
| Examiner Name | Unassigned |
| Attorney Docket Number | 06171.105059 IDX 1017 |

3405771 1

FOREIGN PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages/ Relevant Figures Appear | T ⁴ |
|------------------------|--------------------------|-------------------------|-----------|--------------------------------------|--|---|--|----------------|
| | | Office ³ | Number | Kind Code ² (if known) | | | | |
| TM | BA | WO | 91/18914 | A1 | Vical Inc. | 12-12-1991 | | |
| | BB | WO | 91/19721 | A1 | Glazier | 12-26-1991 | | |
| | BC | WO | 93/00910 | A1 | Vical Inc. | 01-21-1993 | | |
| | BD | WO | 94/26273 | A1 | Hostetler | 11-24-1994 | | |
| | BE | WO | 96/15132 | A1 | Regents of the Univ. of California | 05-23-1996 | | |
| | BF | WO | 99/15194 | A1 | Schering Corporation | 04-01-1999 | | |
| | BG | WO | 99/43691 | A1 | Emory; U. Georgia Res. Found. | 09-02-1999 | | |
| | BH | WO | 99/45016 | A2 | Metabasis Therapeutics Inc. | 09-10-1999 | | |
| | BI | WO | 99/59621 | A1 | Schering Corporation | 11-25-1999 | | |
| | BJ | WO | 99/64016 | A1 | Hoffman-La Roche AG | 12-16-1999 | | |
| | BK | WO | 00/24355 | A1 | Smith & Nephew Kinetic | 05-04-2000 | | |
| | BL | WO | 00/37110 | A2&3 | Schering Corporation | 06-29-2000 | | |
| | BM | WO | 00/52015 | A2&3 | Metabasis Therapeutics | 09-08-2000 | | |
| | BN | WO | 01/18013 | A1 | Metabasis Therapeutics | 03-15-2001 | | |
| | BO | WO | 01/32153 | A2 | Biochem Pharma | 10-05-2001 | | |
| | BP | WO | 01/47935 | A2&3 | Metabasis Therapeutics | 07-05-2001 | | |
| | BQ | WO | 01/60315 | A2 | Biochem Pharma | 08-23-2001 | | |
| | BR | WO | 01/79246 | A2&3 | Pharmasset | 10-25-2001 | | |
| | BS | WO | 01/81359 | A1 | Schering Corporation | 11-01-2000 | | |
| | BT | WO | 01/90121 | A2&3 | Novirio (Idenix); Univ. ... Cagliari | 11-29-2000 | | |
| | BU | WO | 01/92282 | A2&3 | Novirio (Idenix); Univ. ... Cagliari | 06-12-2001 | | |
| | BV | WO | 01/96353 | A2&3 | Novirio Pharm. (Idenix); C.N.R.S. | 21-20-2001 | | |
| | BW | WO | 02/057287 | A2&3 | Merck; Isis Pharmaceuticals | 07-25-2002 | | |
| | BX | WO | 02/057425 | A2 | Merck; Isis Pharmaceuticals | 07-25-2002 | | |
| | BY | WO | 02/18404 | A2&3 | Hoffman-La Roche AG | 03-07-2002 | | |
| | BZ | WO | 02/32414 | A2&3 | Schering Corporation | 04-25-2002 | | |
| | BAA | WO | 02/32920 | A2 | Pharmasset | 04-25-2002 | | |
| | BAB | WO | 02/48165 | A2&3 | Pharmasset | 06-20-2002 | | |
| TM | BAC | WO | 03/024461 | A1 | Schering Corporation | 03-27-2003 | | |

Examiner
Signature

/Traviss McIntosh III/ (07/24/2006)


Date
Considered

07/24/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

3

of

7

Complete if Known

| | |
|------------------------|--------------------------|
| Application Number | 10/609,298 |
| Filing Date | June 27, 2003 |
| First Named Inventor | Sommadossi <i>et al.</i> |
| Group Art Unit | 1623 |
| Examiner Name | Unassigned |
| Attorney Docket Number | 06171.105059 IDX 1017 |

3403771.1

FOREIGN PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages/ Relevant Figures Appear | T ⁶ |
|------------------------|--------------------------|-------------------------|-----------|--------------------------------------|--|---|--|----------------|
| | | Office ² | Number | Kind Code ³ (if known) | | | | |
| TM | CA | WO | 04/003138 | A2 | Merck & Co., Isis Pharmaceutical | 01-08-2004 | | |
| TM | CB | WO | 04/003138 | A2 | Merck & Co., Isis Pharmaceutical | 01-22-2004 | | |
| TM | CC | WO | 04/009020 | A2 | Merck & Co., Isis Pharmaceutical | 01-29-2004 | | |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|------------------------|--------------------------|---|----------------|
| TM | CD | BAGINSKI, S. G. <i>et al.</i> , "Mechanism of action of a pestivirus antiviral compound," <i>PNAS USA</i> , 97(14): 7981-7986 (2000). | |
| | CE | BATTAGLIA, A.M. <i>et al.</i> , "Combination Therapy with Interferon and Ribavirin in the Treatment of Chronic Hepatitis C Infection", <i>Ann. Pharmacother.</i> , 34:487-494 (2000). | ✓ |
| | CF | BERENGUER, M. <i>et al.</i> , "Hepatitis C virus in the transplant setting", <i>Antivir. Ther.</i> , 3 (Suppl 3):125-136 (1998). | ✓ |
| | CG | BERMAN, E. <i>et al.</i> , "Synergistic cytotoxic effect of azidothymidine and recombinant interferon alpha on normal human bone marrow progenitor cells," <i>Blood</i> , 74(4):1281-1286 (1989) | |
| | CH | BHAT <i>et al.</i> (Oral Session V, Hepatitis C Virus, Flaviviridae, 2003 (Oral Session V, Hepatitis C Virus, Flaviviridae; 16 th International Conference on Antiviral Research (April 27, 2003, Savannah, Ga.); p A75). | ✓ |
| | CI | BROWNE, M.J., <i>et al.</i> , "2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-Related Complex: A Phase I trial," <i>J. Infect. Dis.</i> , 167(1):21-29 (1993). | ✓ |
| | CJ | COLACINO, J. M., "Review article: Mechanisms for the anti-hepatitis B virus activity and mitochondrial toxicity of fialuridine (FIAU)," <i>Antiviral Res.</i> , 29(2-3): 125-39 (1996). | ✓ |
| | CK | CUI, L., <i>et al.</i> , "Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-β-D-arabinofuranosyl)-5-iodouracil in human liver cells," <i>J. Clin. Invest.</i> , 95:555-563 (1995). | ✓ |
| | CL | DAVIS, G.L., "Current therapy for chronic Hepatitis C," <i>Gastroenterology</i> 118:S104-S114 (2000). | ✓ |
| | CM | De FRANCESCO, R., <i>et al.</i> , "Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NSSB RNA-dependent RNA polymerase," <i>Antiviral Research</i> , 58: 1-16 (2003). | ✓ |
| TM | CN | De LOMBAERT, S., <i>et al.</i> , "N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors," <i>J. Med. Chem.</i> , 37:498-511 (1994). | ✓ |

| | | | |
|-----------------------|-------------------------------------|--------------------|------------|
| Examiner Signature | /Traviss McIntosh III/ (07/24/2006) | Date Considered | 07/24/2006 |
|-----------------------|-------------------------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

4 of 7

Complete if Known

| | |
|------------------------|--------------------------|
| Application Number | 10/609,298 |
| Filing Date | June 27, 2003 |
| First Named Inventor | Sommadossi <i>et al.</i> |
| Group Art Unit | 1623 |
| Examiner Name | Unassigned |
| Attorney Docket Number | 06171.105059 IDX 1017 |

3405771 1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|------------------------|--------------------------|---|----------------|
| TM | DA | DORNSIFE, R.E., <i>et al.</i> , "In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in Human Immunodeficiency Virus-positive humans," <i>Antimicrob. Agents Chemother.</i> , 40(2):514-519 (1996). | ✓ |
| | DB | DYMOCK, B.W., <i>et al.</i> , "Review: Novel approaches to the treatment of hepatitis C virus infection," <i>Antiviral Chemistry & Chemotherapy</i> , 11(2):79-95 (2000). | |
| | DC | ELDRUP <i>et al.</i> (Oral Session V, Hepatitis C Virus, Flaviviridae; 16 th International Conference on Antiviral Research (April 27, 2003, Savannah, Ga.). | ✓ |
| | DD | FARKAS, J., <i>et al.</i> , "Nucleic acid components and their analogues. XCIV. Synthesis of 6-amino-9-(1-deoxy-β-D-psicofuranosyl)purine", <i>Collect. Czech. Chem. Commun.</i> 32:2663-2667 (1967). | ✓ |
| | DE | FARKAS, J., <i>et al.</i> , "Nucleic acid components and their analogues. LXXIX. Synthesis of methyl 1-deoxy-D-psicofuranosides substituted at C ₍₁₎ with halo atoms or a mercapto group," <i>Collect. Czech. Chem. Commun.</i> , 31:1535-1543 (1996). | ✓ |
| | DF | FARQUHAR, D., <i>et al.</i> , "Synthesis and biological evaluation of neutral derivatives of 3-fluoro-2'-deoxyuridine 5'-phosphate," <i>J. Med. Chem.</i> 26: 1153 (1983); 1153 - 1158. | ✓ |
| | DG | FARQUHAR, D., <i>et al.</i> , "Synthesis and biological evaluation of 9-[5'-(2-oxo-1,3,2-oxazaphosphorinan-2-yl)-β-D-arabinosyl]adenine and 9-[5'-(2-oxo-1,3,2-dioxazaphosphorinan-2-yl)-β-D-arabinosyl]adenine: Potential neutral precursors of 9-[β-D-arabinofuranosyl]adenine 5'-monophosphate," <i>J. Med. Chem.</i> 28:1358-1381 (1985). | ✓ |
| | DH | FERRARI R., <i>et al.</i> , "Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in <i>Escherichia coli</i> ," <i>Journal of Virology</i> , 73(2), 1649-1654 (1999). | ✓ |
| | DI | FISCHL, M.A., <i>et al.</i> , "Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy," <i>Ann. Intern. Med.</i> , 18(10):762-769 (1993). | ✓ |
| | DJ | FREED, J.J., <i>et al.</i> , "Evidence for acyloxymethyl esters of pyrimidine 5'-deoxyribonucleotides as extracellular sources of active 5'-deoxyribonucleotides in cultured cells," <i>Biochemical Pharmacology</i> . 38:3193-3198 (1989). | ✓ |
| | DK | GUNIC, E., <i>et al.</i> , "Synthesis and cytotoxicity of 4'-C- and 5'-C-substituted Toyocamycins," <i>Bioorg. Med. Chem.</i> , 9:163-170 (2001). | ✓ |
| ✓ | DL | HARRY-O'KURU, R.E., J.M. Smith, and M.S. Wolfe, "A short, flexible route toward 2'-C-branched ribonucleosides", <i>J. Org. Chem.</i> 62, 1754-1759 (1997). (Scheme 11). | ✓ |
| TM | DM | HOSTETLER, K.Y., <i>et al.</i> , "Synthesis and antiretroviral activity of phospholipids analogs of azidothymidine and other antiviral nucleosides," <i>J. Biol. Chem.</i> , 265:6112-6117 (1990) | ✓ |

| | | | |
|-----------------------|-------------------------------------|--------------------|------------|
| Examiner Signature | /Traviss McIntosh III/ (07/24/2006) | Date Considered | 07/24/2006 |
|-----------------------|-------------------------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

5

of

7

Complete if Known

| | |
|------------------------|--------------------------|
| Application Number | 10/609,298 |
| Filing Date | June 27, 2003 |
| First Named Inventor | Sommadossi <i>et al.</i> |
| Group Art Unit | 1623 |
| Examiner Name | Unassigned |
| Attorney Docket Number | 06171.105059 IDX 1017 |

3405771 1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS


| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| TM | EA | HOSTETLER, K.Y., <i>et al.</i> , "Greatly enhanced inhibition of Human Immunodeficiency Virus Type I replication in CEM and HT4-6C cells by 3'-deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3'-deoxythymidine," <i>Antimicrob. Agents Chemother.</i> , 36:2025-2029 (September 1992). | ✓ |
| | EB | HUNSTON, R.N., <i>et al.</i> , "Synthesis and biological properties of some cyclic phosphotriesters derived from 2'-deoxy-5-fluorouridine," <i>J. Med. Chem.</i> 27:440-444 (1984). | ✓ |
| | EC | JONES, G. H.; Moffatt, J. G., <i>Methods in Carbohydrate Chemistry</i> ; Whisler, R. L. and Moffatt, J. L. Eds; Academic Press: New York, 1972; 315-322 | ✓ |
| | ED | JONES, G. H., <i>et al.</i> , "4'-substituted nucleosides. 5. Hydroxymethylation of nucleoside 5'-aldehydes," <i>J. Org. Chem.</i> , 44:1309-1317 (1979). | ✓ |
| | EE | KHAMNEI, S., "Neighboring group catalysis in the design of nucleotide prodrugs," <i>J. Med. Chem.</i> , 39:4109-4115 (1996). | ✓ |
| | EF | KUCERA, L.S., <i>et al.</i> , "Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation," <i>AIDS Res. Hum. Retro Viruses</i> , 6:491-501 (1990). | ✓ |
| | EG | KURTZBERG J., <i>et al.</i> , "Differential toxicity of carbovir and AZT to human bone marrow hematopoietic progenitor cells in vitro," <i>Exp. Hematol.</i> , 18(10):1094-1096 (1990). | ✓ |
| | EH | LEONARD, N. J., <i>et al.</i> , "5-Amino-5-deoxyribose derivatives. Synthesis and use in the preparation of "reversed" nucleosides" <i>J. Heterocycl. Chem.</i> , 3:485-489 (December 1966). | ✓ |
| | EI | LERZA, R., <i>et al.</i> , "In vitro synergistic inhibition of human bone marrow hemopoietic progenitor growth by a 3'-azido-3'-deoxy-thymidine, 2',3'-dideoxycytidine combination," <i>Exp. Hematol.</i> , 25(3):252-255 (1997). | ✓ |
| | EJ | LEWIS W., <i>et al.</i> , "Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria," <i>J. Clin. Invest.</i> , 89(4):1354-1360 (1992). | ✓ |
| | EK | LEWIS, L. D., <i>et al.</i> , "Ultrastructural changes associated with reduced mitochondrial DNA and impaired mitochondrial function in the presence of 2'3'-dideoxycytidine," <i>Antimicrob. Agents Chemother.</i> , 36(9):2061-2065 (1992). | ✓ |
| | EL | LEWIS, W., <i>et al.</i> , "Fialuridine and its metabolites inhibit DNA polymerase γ at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts," <i>Proceedings of the National Academy of Sciences, USA</i> , 93(8): 3592-7 (1996). | ✓ |
| ✓ | EM | LOHMANN V., <i>et al.</i> , "Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the Hepatitis C virus," <i>Virology</i> , 249, 108-118 (1998). | ✓ |
| TM | EN | LUH, T.-Y., <i>et al.</i> , "A convenient method for the selective esterification of amino-alcohols," <i>Synthetic Communications</i> , 8(5):327-333 (1978). | ✓ |

| | | | |
|--------------------|-------------------------------------|-----------------|------------|
| Examiner Signature | /Traviss McIntosh III/ (07/24/2006) | Date Considered | 07/24/2006 |
|--------------------|-------------------------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

6 of 7

Complete if Known

| | |
|------------------------|-----------------------|
| Application Number | 10/609,298 |
| Filing Date | June 27, 2003 |
| First Named Inventor | S mmadosi et al. |
| Group Art Unit | 1623 |
| Examiner Name | Unassigned |
| Attorney Docket Number | 06171.105059 IDX 1017 |

3405771 1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| TM | FA | MCCORMICK, J., et al., "Structure and total synthesis of HF-7, a neuroactive glyconucleoside disulfate from he funnel-web spide <i>Hololena curta</i> ," <i>J. Am. Chem. Soc.</i> , 121(24), 5661-5664 (1999). | ✓ |
| | FB | MCKENZIE, R., et al., "Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B", <i>N. Engl. J. Med.</i> , 333(17):1099-1105 (1995). | ✓ |
| | FC | MEDINA, D. J., et al., "Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-Human Immunodeficiency Virus dideoxynucleosides," <i>Antimicrob. Agents Chemother.</i> , 38(8):1824-8 (1994). | ✓ |
| | FD | MEIER, C., et al., "Cyclic saligenyl phosphotriesters of 2',3'-dideoxy-2',3'-didehydrothymidine (d4T) – A new pro-nucleic approach." <i>Bioorganic & Med. Chem. Letters</i> 7(2):99-104 (1997). | ✓ |
| | FE | MEYER, R.B., Jr., et al., "2'-O-Acyl-6-thioinosine cyclic 3',5'-phosphates as prodrugs of thioinosinic acid," <i>J. Med. Chem.</i> 22: 811-815 (1979). | ✓ |
| | FF | NEIDLEIN, R., et al., "Mild preparationof 1-benzyloxyiminoalkylphosphonic dichlorides: Application to the synthesis of cyclic phosphonic diesters and cyclic monoester amides," <i>Heterocycles</i> 35:1185-1203 (1993). | ✓ |
| | FG | NUTT, R.F., et al., "Branched-chain sugar nucleosides. III. 3'-C-methyladenine", <i>J.Org. Chem.</i> , 33:1789-1795 (1968). | ✓ |
| | FH | OLSEN, et al. (Oral Session V, Hepatitis C Virus, Flaviviridae; 16 th International Conference on Antiviral Research (April 27, 2003, Savannah, Ga.) p A76). | ✓ |
| | FH | PAN-ZHOU, X-R, et al., "Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells," <i>Antimicrob. Agents Chemother.</i> 44:496-503 (2000). | ✓ |
| | FJ | PIANTADOSI, C., et al., "Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity," <i>J. Med. Chem.</i> 34:1408-1414 (1991). | ✓ |
| | FK | RICHMAN, D.D., et al., "The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-Related Complex," <i>N. Engl. J. Med.</i> , 317(4):192-197 (1987). | ✓ |
| | FL | SOMMADOSSI J-P, et al., "Comparison of cytotoxicity of the (-)- and (+)- enantiomer of 2',3'-dideoxy-3'-thiacytidine in normal human bone marrow progenitor cells," <i>Biochemical Pharmacology</i> 44(10):1921-1925 (1992). | ✓ |
| ✓ | FM | SOMMADOSSI J.-P., et al., "Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro," <i>Antimicrobial Agents and Chemotherapy</i> , 31:452-454 (1987). | ✓ |
| TM | FN | STARRETT, J.E.Jr., et al., "Synthesis, oral bioavailability determination, and <i>in vitro</i> evaluation of prodrugs of the antiviral agents 9-(2-(phosphonomethoxy)ethyl)adenine (PMEA)," <i>J. Med. Chem.</i> 37: 1857-1864 (1994). | |

| | | | |
|--------------------|-------------------------------------|-----------------|------------|
| Examiner Signature | /Traviss McIntosh III/ (07/24/2006) | Date Considered | 07/24/2006 |
|--------------------|-------------------------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

7

of

7

Complete if Known

| | |
|------------------------|-------------------------|
| Application Number | 10/609,298 |
| Filing Date | June 27, 2003 |
| First Named Inventor | S mmadosi <i>et al.</i> |
| Group Art Unit | 1623 |
| Examiner Name | Unassigned |
| Attorney Docket Number | 06171.105059 IDX 1017 |

3405771_1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| TM | GA | WEINBERG, R.S., <i>et al.</i> , "Effect of antiviral drugs and hematopoietic growth factors on <i>in vitro</i> erythropoiesis," <i>Mt. Sinai J. Med.</i> 1998;65(1):5-13. | ✓ |
| TM | GB | YARCHOAN, R., <i>et al.</i> "Long-term toxicity / activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex," <i>The Lancet</i> , 336(8714):526-529 (1990). | ✓ |
| TM | GC | YOSHIDA Y, <i>et al.</i> , "Reversal of azidothymidine-induced bone marrow suppression by 2',3'-dideoxythymidine as studied by hemopoietic clonal culture," <i>AIDS Res. Hum. Retroviruses</i> , 6(7):929-932 (1990). | ✓ |
| TM | GD | ZON, G., "Cyclophosphamide Analogues," Chapter 4 in <i>Progress in Medicinal Chemistry</i> , Vol. 19, G.P. Ellis and G.B. West, Eds., pp. 205-246 (1982). | ✓ |

3405771_1


| | | | |
|--------------------|-------------------------------------|-----------------|------------|
| Examiner Signature | /Traviss McIntosh III/ (07/24/2006) | Date Considered | 07/24/2006 |
|--------------------|-------------------------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Please type a plus sign (+) inside this box → ☐

Continuation of form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

| | |
|------------------------|--------------------------|
| Application Number | 10/609,298 |
| Filing Date | June 27, 2003 |
| First Named Inventor | Sommadossi <i>et al.</i> |
| Group Art Unit | 1623 |
| Examiner Name | Unassigned |
| Attorney Docket Number | 06171.105059 IDX 1017 |

3405771_1

U.S. PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pp., Columns, Lines, Where Relevant Passages/Relevant Figures Appear | T ⁶ |
|------------------------|--------------------------|----------------------|-------------------------|--|--|---|----------------|
| | | Number | Kind Code (if known) | | | | |
| | | | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pp., Columns, Lines, Where Relevant Passages/ Relevant Figures Appear | T ⁶ |
|------------------------|--------------------------|-------------------------|-----------|--------------------------------------|--|---|--|----------------|
| | | Office ³ | Number | Kind Code ² (if known) | | | | |
| TM | AA | EP | 0 747 389 | | Taiho Pharmaceutical Co. | 12-11-1996 | | |
| TM | AB | GB | 1 163 102 | | MERCK & Co. | 09-04-1969 | | |
| TM | AC | GB | 1 163 103 | | MERCK & Co. | 09-04-1969 | | |
| TM | AD | GB | 1 209 654 | | MERCK & Co. | 10-21-1970 | | |
| | | | | | | | | |
| | | | | | | | | |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), Volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|------------------------|--------------------------|--|----------------|
| TM | AE | AWANO, H. <i>et al.</i> , "Synthesis and Antiviral Activity of 5-Substitute (2'S)-2'-C-Methylcytidines and -Uridines ¹¹¹ " Nucleosides and Nucleoties, Part 144 ARCHIV DER PHARMAZIE, VCH VERLAGSGESELLSCHAFT MBH, WEINHEIM, DE, Vol. 329, 01 February 1996 (1996-02-01), pp. 66-72 | |
| TM | AF | BEIGELMAN <i>et al.</i> , "A General Method for Synthesis of 3'-C-Alkyl nucleosides" Nucleic Acids Symposium. Series No. 9., IRL Press, Oxford, GB, Vol. 9, no. 9, 06 September 1981 (1981-09-06), pp. 115-118 | |
| TM | AG | CAPPELLACCI, <i>et al.</i> "Ribose-Modified Nucleosides as Ligands for Adenosine Receptors: Synthesis, Conformational Analysis, and Biological Evaluation of 1'-C-Methyl Adenosine Analogues Journal Of Medicinal Chemistry, American Chemical Society, 45. pp. 1196-1202 | |
| DUPLICATE | AH | FARKAS, J. <i>et al.</i> , Nucleic Acids Components and Their Analogues. XCIV. Synthesis of 6-Amino-9(1-Deoxy-Beta-D Psicofuranosyl) P Urine, Collection of Czechoslovak Chemical Communications, Academic Press, London GB, Vol. 32, no. 7, 1967, pp. 2663-2667 | |

Examiner
Signature

/Traviss McIntosh III/ (07/24/2006)

Date
Considered

07/24/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | |
|--|----|--------------------------|--------------------------|-----------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | |
| | | Application Number | 10/609,298 | |
| | | Filing Date | June 27, 2003 | |
| | | First Named Inventor | Sommadossi <i>et al.</i> | |
| | | Group Art Unit | 1623 | |
| | | Examiner Name | Unassigned | |
| 2 | of | 3 | Attorney Docket Number | 06171.105059 IDX 1017 |

3405771-1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

DUPL

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), Volume-issue number(s), publisher, city and/or country where published. | T ⁴ |
|---------------------|-----------------------|--|----------------|
| TM | BA | FEDEROV, I.I., <i>et al.</i> , "3'-C-Branched 2'-Deoxy-5-Methyluridines: Synthesis, Enzyme Inhibition, and Antiviral Properties" Journal of Medicinal Chemistry, American Chemical Society, Washington, US, Vol. 35, 1992, pp. 4567-4575 | |
| TM | BB | FRANCHETTI, P., <i>et al.</i> , "2'-C-Methyl Analogues Of Selective Adenosine Receptor Agonists: Synthesis And Binding Studies", Journal of Medicinal Chemistry, American Chemical Society, Washington, US, Vol. 41, 1998, pp. 1708-1715 | |
| TM | BC | HARRY O'KURU <i>et al.</i>, "A Short, Flexible Route Toward 2'-C-Branched Ribonucleosides" Journal of Org. Chemistry, American Chemical Society, Vol. 62, pp. 1754-1759 | |
| TM | BD | H. HATTORI, <i>et al.</i> , "Nucleosides and Nucleotides 158" Journal of Medicinal Chemistry, American Chemical Society, Vol. 39, 1996, pp. 5005-5001 | |
| TM | BE | HREBABECKY, H. <i>et al.</i> , "Nucleic Acid Components and their Analogues. CXLIX. Synthesis of Pyrimidine Nucleosides Derived from 1-Deoxy-D-Psicose", Collection of Czechoslovak Chemical Communications, Academic Press, London, GB, Vol. 37, 1972, pp. 2059-2065 | |
| TM | BF | HREBABECKY, H. <i>et al.</i> , "Synthesis of 7- and 9β-D Psicofuranosylguanine and their 1' -Deoxy Derivatives", Collection of Czechoslovak Chemical Communication, Academic Press, London, GB, Vol. 39, 1974, pp. 2115-2123 | |
| TM | BG | JOHNSON, <i>et al.</i> , "Nucleosides & Nucleotides -- 3'-C-TrifluoromethylRibonucleoside", Marcel Dekker, Inc., US, Vol. 14, no. 1/2, 1995, pp. 185-194 | |
| TM | BH | LI, Nan-Sheng <i>et al.</i> , "2'-C-Branched Ribonucleosides. 2. Synthesis of 2'-C-β-Trifluoromethyl Pyrimidine Ribonucleosides, Organic Letters, Vol. 3, No. 7, 2001, pp. 1025-1028 | |
| TM | BI | MATSUDA, A. <i>et al.</i> , "Radical Deoxygenation of Tert-Alcohols in 2'-Branched-Chain Sugar Pyrimidine Nucleosides :Synthesis and Antileukemic Activity of 2' -Deoxy-2' (S)-Methylcytidine" Chemical and Pharmaceutical Bulletin, Pharmaceutical Society of Japan, Tokyo, JP, Vol. 35, 1987, pp. 3967-3970 | |
| TM | BJ | MATSUDA, A. <i>et al.</i> , "Nucleosides and Nucleotides. 94. Radical Deoxygenation of Tert-Alcohols in 1-(2-C-alkylpentafuranosyl) Pyrimidines : Synthesis of (2'S)-2-Deoxy-2'-C-Methylcytidine, an Antileukemic Nucleoside " Journal of Medicinal Chemistry, American Chemical Society. Washington, US, Vol. 34, 1991, pp. 234-239 | |
| TM | BK | MIKHAILOV, S. N. <i>et al.</i> , "Synthesis and Properties of 3'-C-Methylnucleosides and their Phosphoric esters" Carbohydrate Research, Elsevier Scientific Publishing Company, Amsterdam, NL, Vol. 124, 1983, pp. 75-96 | |
| TM | BL | MURAL, Y. <i>et al.</i> , "A Synthesis and an X-ray Analysis of 2' -C-, 3' -C- and 5' -C- Methylsangivamycins" HETEROCYCLES, Vol. 33, no. 1, 1992, pp. 391-404 | |

| | | | |
|--------------------|-------------------------------------|-----------------|------------|
| Examiner Signature | /Traviss McIntosh III/ (07/24/2006) | Date Considered | 07/24/2006 |
|--------------------|-------------------------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|--------------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/609,298 |
| | | | | Filing Date | June 27, 2003 |
| | | | | First Named Inventor | Sommadossi <i>et al.</i> |
| | | | | Group Art Unit | 1623 |
| | | | | Examiner Name | Unassigned |
| | | | | Attorney Docket Number | 06171.105059 IDX 1017 |
| | 3 | of | 3 | | |

3405771_1

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | | | |
|---|--------------------------|--|--|--|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), Volume-issue number(s), publisher, city and/or country where published. | | | T ⁶ |
| TM | CA | ONG <i>et al.</i> , "Synthesis of 3'-C-Methyladenosine and 3'-C-Methyluridine Diphosphates and their Interaction with the Ribonucleoside Diphosphate Reductase from <i>Corynebacterium Nephridii</i> " Biochemistry, American Chemical Society, Vol. 31, No. 45, 1992, pp. 11210-11215 | | | |
| TM | CB | ROSENTHAL, A. <i>et al.</i> , "Branched-Chain Sugar Nucleosides. Synthesis of 3'-C-Ethyl (and 3'-C-Butyl) Uridine" Carbohydrate Research, Elsevier Scientific Publishing Company, Amsterdam, NL, Vol. 79, 1980, pp. 235-242 | | | |
| TM | CC | SCHMIT, C., "Synthesis of 2'-Deoxy-2'- α -Monofluoromethyl and Trifluoromethyl Nucleoside" SYNLETT, Thieme Verlag, Stuttgart, DE, no. 4, 1994, pp. 241-242 | | | |
| TM | CD | SHARMA P.K., <i>et al.</i> , "Synthesis of 3'-Trifluoromethyl Nucleosides as Potential Antiviral Agents" Nucleosides, Nucleotides And Nucleic Acids, Marcel Dekker, Ann Arbor, Mi, US. Vol. 19, no. 4. 2000, pp. 757-774 | | | |
| TM | CE | TRONCHET <i>et al.</i> , (72) "Synthese et desamination enzymatique des, C-hydroxymethyl-3'-et, C-methyl-3'-beta-D-xylofurannosyl-9-adenines" Helvetica Chimica Acta, Vol. 62, 1979, pp. 689-695 | | | |
| TM | CF | WOLF J. <i>et al.</i> , "New 2'-C-Branched-Chain Sugar Nucleoside Analogs With Potential Antiviral or Antitumor Activity, Synthesis" Georg Thieme Verlag, Stuttgart, DE, no. 8, August 1992 (1992-08), pp. 773-778 | | | |

3405771_1

| | | | |
|-----------------------|-------------------------------------|--------------------|------------|
| Examiner Signature | /Traviss McIntosh III/ (07/24/2006) | Date Considered | 07/24/2006 |
|-----------------------|-------------------------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|------------------------|-------------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/609,298 |
| | | | | Filing Date | June 27, 2003 |
| | | | | First Named Inventor | LaColla |
| | | | | Group Art Unit | 1623 |
| | | | | Examiner Name | Traviss C. McIntosh III |
| | | | | Attorney Docket Number | 06171.105059 (IDX 1017) |
| Sheet | 1 | of | 4 | | |



3405786 1

DUPLICATE

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|-----------------------|----------------------|----------------------|---|--|--|----------------|
| Examiner Initials * | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages/Relevant Figures Appear | T ⁶ |
| | | Number | Kind Code (if known) | | | | |
| TM | AA | 4,814,477 | | Wijnberg <i>et al.</i> | 03-21-1989 | | |
| TM | AB | 4,952,740 | | Sylvain <i>et al.</i> | 08-28-1990 | | |
| | AC | 5,323,263 | | Hostetler <i>et al.</i> | 06-29-1993 | | |
| TM | AD | 5,780,617 | | van den Bosch <i>et al.</i> | 05-31-1994 | | |
| | AE | 5,696,277 | | Hostetler <i>et al.</i> | 12-09-1997 | | |
| | AF | 5,763,418 | | Matsuda <i>et al.</i> | 06-09-1998 | | |
| | AG | 5,789,608 | | Glazier | 08-04-1998 | | |
| | AH | 6,172,046 | | Albrecht | 01-09-2001 | | |
| | AI | 6,252,060 | | Hostetler <i>et al.</i> | 06-26-2001 | | |
| | AJ | 2003/0008841 | | Devos <i>et al.</i> | 08-07-2001 | | |
| | AK | 6,277,830 | | Ganguly <i>et al.</i> | 08-21-2001 | | |
| | AL | 6,348,587 | | Schinazi <i>et al.</i> | 02-19-2002 | | |
| | AM | 2002/0055483 | | Watanabe <i>et al.</i> | 05-09-2002 | | |
| | AN | 2002/0055473 | | Ganguly <i>et al.</i> | 05-09-2002 | | |
| | AO | 2002/0095033 | | Ramasamy <i>et al.</i> | 07-18-2002 | | |
| | AP | 6,436,437 | | Yatvin <i>et al.</i> | 08-20-2002 | | |
| | AQ | 6,448,392 | | Hostetler <i>et al.</i> | 09-10-2002 | | |
| | AR | 6,448,392 | | Hostetler <i>et al.</i> | 09-10-2002 | | |
| | AS | 2002/0127203 | | Albrecht | 09-12-2002 | | |
| | AT | 6,472,373 | | Albrecht | 10-29-2002 | | |
| | AU | 6,495,677 | | Ramasamy <i>et al.</i> | 12-17-2002 | | |
| | AV | 2002/0198171 | | Schinazi <i>et al.</i> | 12-26-2002 | | |
| | AW | 2003/0008841 | | Devos <i>et al.</i> | 01-09-2003 | | |
| | AX | 2003/0050229 | | LaColla <i>et al.</i> | 03-13-2003 | | |
| | AY | 2003/0055013 | | Brass | 03-20-2003 | | |
| | AZ | 2003/0053986 | | Zahm | 03-20-2003 | | |
| | AAA | 2003/0060400 | | LaColla <i>et al.</i> | 03-27-2003 | | |
| TM | AAB | 2003/0087873 | | Stuyver <i>et al.</i> | 05-08-2003 | | |

| | | | |
|--------------------|-------------------------------------|-----------------|------------|
| Examiner Signature | /Traviss McIntosh III/ (07/24/2006) | Date Considered | 07/24/2006 |
|--------------------|-------------------------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐


PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid control number.

| | | | |
|--|--|--------------------------|-------------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/609,298 |
| | | Filing Date | June 27, 2003 |
| | | First Named Inventor | LaColla |
| | | Group Art Unit | 1623 |
| | | Examiner Name | Traviss C. McIntosh III |
| | | Attorney Docket Number | 06171.105059 (IDX 1017) |



3405786 1

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|-----------------------|----------------------|----------------------|---|--|--|----------------|
| Examiner Initials * | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages/Relevant Figures Appear | T ⁶ |
| | | Number | Kind Code (if known) | | | | |
| TM | BA | 6,566,365 | | Storer <i>et al.</i> | 05-20-2003 | | |
| | BB | 6,573,248 | | Ramasamy <i>et al.</i> | 06-03-2003 | | |
| | BC | 6,599,887 | | Hostetler <i>et al.</i> | 07-29-2003 | | |
| | BD | 2003/0225029 | | Stuyver <i>et al.</i> | 12-04-2003 | | |
| | BE | 6,660,721 | | Devos <i>et al.</i> | 12-09-2003 | | |
| | BF | 2004/0002476 | | Stuyver <i>et al.</i> | 01-01-2004 | | |
| | BG | 2004-0023921 | | Yao <i>et al.</i> | 02-05-2004 | | |
| | BH | 2004/0059104 | | Cook <i>et al.</i> | 03-25-2004 | | |
| | BI | 2004/0063658 | | Roberts <i>et al.</i> | 04-01-2004 | | |
| | BJ | 2004/0067901 | | Bhat <i>et al.</i> | 04-08-2004 | | |
| | BK | 2004/0072788 | | Bhat <i>et al.</i> | 04-15-2004 | | |
| | BL | 2004/0077587 | | Sommadossi <i>et al.</i> | 04-22-2004 | | |
| | BM | 2004/0110717 | | Bhat <i>et al.</i> | 06-10-2004 | | |
| | BN | 2004/0110718 | | Devos <i>et al.</i> | 06-10-2004 | | |
| | BO | 6,752,981 | | Erion <i>et al.</i> | 06-22-2004 | | |
| | BP | 2004/0147464 | | Roberts <i>et al.</i> | 07-29-2004 | | |
| | BQ | 6,777,395 | | Bhat <i>et al.</i> | 08-17-2004 | | |
| | BR | 6,784,166 | | Devos <i>et al.</i> | 08-31-2004 | | |
| | BS | 6,784,161 | | Ismaili <i>et al.</i> | 08-31-2004 | | |
| | BT | 2004/0266722 | | Devos <i>et al.</i> | 12-30-2004 | | |
| | BU | 2004/0266723 | | Otto <i>et al.</i> | 12-30-2004 | | |
| | BV | 2005/0009737 | | Clark <i>et al.</i> | 01-13-2005 | | |
| | BW | 6,846,810 | | Martin <i>et al.</i> | 01-25-2005 | | |
| | BX | 6,875,751 | | Imbach <i>et al.</i> | 04-05-2005 | | |
| | BY | 2005/0119200 | | Roberts <i>et al.</i> | 06-02-2005 | | |
| | BZ | 6,911,424 | | Schinazi <i>et al.</i> | 06-28-2005 | | |
| TM | BAA | 6,965,066 | | Jiang <i>et al.</i> | 11-15-2005 | | |

| | | | |
|--------------------|-------------------------------------|-----------------|------------|
| Examiner Signature | /Traviss McIntosh III/ (07/24/2006) | Date Considered | 07/24/2006 |
|--------------------|-------------------------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | | |
|---|--|---|----|--------------------------|-------------------------|--|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Complete if Known | | |
| | | | | Application Number | 10/609,298 | |
| | | | | Filing Date | June 27, 2003 | |
| | | | | First Named Inventor | LaColla | |
| | | | | Group Art Unit | 1623 | |
| | | | | Examiner Name | Traviss C. McIntosh III | |
| | | | | Attorney Docket Number | 06171.105059 (IDX 1017) | |
| | | 3 | of | 4 | | |

3405786 1

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|--------------------------|-------------------------|-----------|--------------------------------------|--|---|--|----------------|
| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages/ Relevant Figures Appear | T ⁶ |
| | | Office ³ | Number | Kind Code ² (if known) | | | | |
| TM | CA | FR | 1 521 076 | | Merck & Co. Inc. | 04-12-1968 | | |
| | CB | JP | 06211890 | | Yamasa Shoyu Co. Ltd. | 08-02-1994 | | |
| | CC | JP | 06 228186 | | Yamasa Shoyu Co. Ltd. | 08-16-1994 | | |
| | CD | WO | 03/051899 | | Girardet <i>et al.</i> | 06-26-2003 | | |
| | CE | WO | 03/061385 | | An <i>et al.</i> | 07-31-2003 | | |
| | CF | WO | 03/061576 | | An <i>et al.</i> | 07-31-2003 | | |
| | CG | WO | 03/062256 | | An <i>et al.</i> | 07-31-2003 | | |
| | CH | WO | 03/062257 | | An <i>et al.</i> | 07-31-2003 | | |
| | CI | WO | 03/062255 | | Hong <i>et al.</i> | 07-31-2003 | | |
| | CJ | WO | 03/105770 | | Bhat Balkrishen | 12-24-2003 | | |
| | CK | WO | 04/000858 | | Carroll <i>et al.</i> | 12-31-2003 | | |
| ✓ | CL | WO | 04/007512 | A2 | Merck & Co., Isis Pharmaceutical | 01-22-2004 | | |
| TM | CM | WO | 06/012440 | A2 | Wang <i>et al.</i> | 02-02-2006 | | |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | | |
|---|--------------------------|--|--|----------------------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | T ⁶ |
| TM | CN | BIANCO A., <i>et al.</i> , "Synthesis of a New Carbocyclic Nucleoside Analog", <i>Tetrahedron Letters</i> , 38(36): 6433-6436, 1997 | | |
| TM | CO | CHIACCHIO U. <i>et al.</i> , "Stereoselective Synthesis of 2'-amino-2',3'-dideoxynucleosides by Nitron 1,3-Dipolar Cycloaddition: A New Efficient Entry Toward d4T and its 2-Methyl Analogue", <i>J. Org. Chem.</i> , 64: 28-36 (1999). | | |
| TM | CP | CZERNECKI S. <i>et al.</i> , "Synthesis of 2'-deoxy-2'-spirocyclopropyl Cytidine as Potential Inhibitor of Ribonucleotide Diphosphate Reductase", <i>Can. J. Chem.</i> , 71: 413-416 (1993). | | |
| TM | CQ | HASSAN, A.E.A., <i>et al.</i> , "Nucleosides and Nucleotides. 156. Chelation-Controlled and Nonchelation-Controlled Diastereofacial Selective Thiophenol Addition Reactions at the 2'-Position of 2'-[(Alkoxy carbonyl)methylene]-2'-deoxyuridines: Conversion of (Z)-2'-[(Alkoxy carbonyl)methylene]-2'-Deoxyuridines into Their (E)-Isomers", <i>J. Org. Chem.</i> , 62: 11-17 (1997). | | |
| TM | CR | HASSAN, A.E.A., <i>et al.</i> , "Nucleosides and Nucleotides. 151. Conversion of (Z)-2'-(Cyanomethylene)-2'-Deoxyuridines into Their (E)-Isomers via Addition of Thiophenol to the Cyanomethylene Moiety Followed by Oxidative Syn-elimination Reactions", <i>J. Org. Chem.</i> , 61: 6261-6267 (1996). | | |
| Examiner Signature | | /Traviss McIntosh III/ (07/24/2006) | | Date Considered 07/24/2006 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|-------------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/609,298 |
| | | | | Filing Date | June 27, 2003 |
| | | | | First Named Inventor | LaColla |
| | | | | Group Art Unit | 1623 |
| | | | | Examiner Name | Traviss C. McIntosh III |
| | | | | Attorney Docket Number | 06171.105059 (IDX 1017) |
| | 4 | of | 4 | | |

3405786_1

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | | |
|---|--------------------------|--|----------------|--|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ | |
| TM | DA | HOSSAIN N., et al., "Synthesis of 2'- And 3'-Spiro-Isoxazolidine Derivatives of Thymidine& Their Conversions To 2', 3'-Dideoxy-2', 3'-Didehydro-3'-C-Substituted Nucleosides by Radical Promoted Fragmentation", <i>Tetrahedron</i> , 49: 10133-10156 (1993). | | |
| TM | DB | MAHMOUDIAN M. et al., "A Versatile Procedure for the Generation of Nucleoside 5-'Carboxylic Acids Using Nucleoside Oxidase", <i>Tetrahedron</i> , 54: 8171-8182 (1998). | | |
| TM | DC | VELAZQUEZ, S., et al., "Synthesis of [1-[3',5'-bis-O-(tert-butyldimethylsilyl)-β-D-arabino- and β-D-ribofuranosyl] cytosine]-2'-spiro-5''-(4''-amino-1'', 2''-oxathiole-2'', 2''-dioxide). Analogues of the Highly Specific Anti-HIV-1 agent TSAO-T", <i>Tetrahedron</i> , 50: 11013-11022 (1994). | | |

3405786_1

| | | | |
|-----------------------|-------------------------------------|--------------------|------------|
| Examiner Signature | /Traviss McIntosh III/ (07/24/2006) | Date Considered | 07/24/2006 |
|-----------------------|-------------------------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.